Skip to main content

Table 2 Number of patients in each subgroup defined by SEP-e′ and E/SEP-e′

From: Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial

Subgroups

Number of patients

Canagliflozin

Glimepiride

SEP-e′: < 4.7

33

40

SEP-e′: 4.7–6.4

36

36

SEP-e′: ≥ 6.4

36

36

SEP-e′: missing

8

8

E/SEP-e′: < 10.2

34

38

E/SEP-e′: 10.2–13.9

35

37

E/SEP-e′: ≥ 13.9

34

37

E/SEP-e′: missing

10

8

  1. See abbreviations in Table 1
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840